Eli Lilly’s (NYSE: LLY) newly launched oral weight loss drug continues to gain rapid traction with patients and physicians, racking up 5,612 prescriptions in the United States during its third week on the market, according to analysts citing IQVIA data.
The early prescription volume signals strong commercial momentum for the pharmaceutical giant as it pushes deeper into the booming GLP-1 weight loss category. Moreover, the figures arrive at a time when oral alternatives to injectable therapies are drawing intense interest from both patients seeking convenience and investors tracking the next phase of the obesity drug market.
Lilly’s stock reflected the positive sentiment, climbing 9.80% as Wall Street digested the latest uptake numbers.
The post Eli Lilly’s Oral Weight Loss Drug Hits 5,600+ Prescriptions in Third Week on Market appeared first on PRISM MarketView.
